Lupin’s arm gets USFDA approval for generic Combivir tablets

31 Oct 2011 Evaluate

Pharma Major, Lupin’s US subsidiary - Lupin Pharmaceuticals, Inc. (LPI) has received tentative approval for its Lamivudine and Zidovudine tablets, 150 mg/300 mg from the United States Food and Drugs Administration (USFDA) for the company's abbreviated new drug application (ANDA) to market a generic version of Combivir tablets, 150 mg/300 tug of ViiV Healthcare.

Lupin's Lamivudine and Zidovudine tablets are the AB-rated generic equivalent of ViiV Healthcare's Combivir tablets, 150 mg/300 mg. Lamivudine - Zidovudine is a combination of two nucleoside analogue reverse transcriptase inhibitors and is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

According to IMS Health sales data, Combivir tablets, 150 mg/300 mg had annual US sales of approximately $295 million for the twelve months ending June 2011.

Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. Lupin has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.

Lupin Share Price

2069.95 26.65 (1.30%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.